3rd International Definiens Symposium to be Held in Munich from June 14-16, 2012
News Apr 23, 2012
Definiens® invites professionals interested in pathology and biomarker development to the 3rd International Definiens Symposium. The symposium will be held at the Definiens headquarters in Munich from June 14-16, 2012.
The annual event is the premier forum for the latest trends in quantitative research in histology, tissue-based biomarker development and cutting-edge biomedical image and data analysis. It brings together experts from around the world to share best practices and experiences. This year’s keynote lecture will be delivered by Dr. Frauke Bentzien from Exelixis, one of the pioneers in quantitative digital pathology who has been successfully applying this new paradigm in preclinical safety studies and clinical trials for many years.
The Definiens Symposium offers attendees the opportunity to network with peers and renowned experts and learn from their approaches and experiences. A one-day pre-conference workshop will provide hands-on experiences and training on the latest Definiens solutions for image analysis and data mining.
Nobel Laureate Prof. Gerd Binnig, Founder and CTO Definiens, will share his vision for the next generation of pathology tools, while leading experts from Roche, AstraZeneca, Novartis, GlaxoSmithKline and Johnson & Johnson, as well as practitioners from other renowned institutions, will contribute insights from their work. To find the full speaker panel and the workshop program, visit http://www.definiens.com/community/symposium.html.
“We are delighted to have such a distinguished group of speakers,” stated Thomas Heydler, CEO of Definiens. “The digital pathology market is quickly transitioning into a second phase of adoption where quantitative approaches allow us to unveil the real value of digital slides and are currently transforming pathology into a quantitative discipline. By bringing together thought leaders, experts and users, the International Definiens Symposium provides a very stimulating forum for learning about the future of this exciting field.”
Pathway in Neurons may Contribute to Neurodegenerative DiseaseNews
Pathway has received attention as potential drug target.READ MORE